These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29915391)

  • 1. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
    Brough R; Gulati A; Haider S; Kumar R; Campbell J; Knudsen E; Pettitt SJ; Ryan CJ; Lord CJ
    Oncogene; 2018 Oct; 37(43):5701-5718. PubMed ID: 29915391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Inhibition of the E3 Ligase SCF
    Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
    Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
    Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
    J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.
    Gupta P; Zhao H; Hoang B; Schwartz EL
    Br J Cancer; 2022 Oct; 127(6):969-975. PubMed ID: 35752713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
    Wu Q; Ba-Alawi W; Deblois G; Cruickshank J; Duan S; Lima-Fernandes E; Haight J; Tonekaboni SAM; Fortier AM; Kuasne H; McKee TD; Mahmoud H; Kushida M; Cameron S; Dogan-Artun N; Chen W; Nie Y; Zhang LX; Vellanki RN; Zhou S; Prinos P; Wouters BG; Dirks PB; Done SJ; Park M; Cescon DW; Haibe-Kains B; Lupien M; Arrowsmith CH
    Nat Commun; 2020 Aug; 11(1):4205. PubMed ID: 32826891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells.
    Bulanova D; Akimov Y; Senkowski W; Oikkonen J; Gall-Mas L; Timonen S; Elmadani M; Hynninen J; Hautaniemi S; Aittokallio T; Wennerberg K
    Sci Adv; 2024 May; 10(21):eadj1564. PubMed ID: 38781347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression and prognosis analyses of GLUT1-4 and RB1 in breast cancer.
    Zhang X; Pang X; Zhang Z; Liu Q; Zhang H; Xiang Q; Cui Y
    BMC Cancer; 2021 Sep; 21(1):1026. PubMed ID: 34525987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the
    Gong X; Du J; Parsons SH; Merzoug FF; Webster Y; Iversen PW; Chio LC; Van Horn RD; Lin X; Blosser W; Han B; Jin S; Yao S; Bian H; Ficklin C; Fan L; Kapoor A; Antonysamy S; Mc Nulty AM; Froning K; Manglicmot D; Pustilnik A; Weichert K; Wasserman SR; Dowless M; Marugán C; Baquero C; Lallena MJ; Eastman SW; Hui YH; Dieter MZ; Doman T; Chu S; Qian HR; Ye XS; Barda DA; Plowman GD; Reinhard C; Campbell RM; Henry JR; Buchanan SG
    Cancer Discov; 2019 Feb; 9(2):248-263. PubMed ID: 30373917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.
    Jovanović B; Church SE; Gorman KM; North K; Richardson ET; DiLullo M; Attaya V; Kasparian J; Mohammed-Abreu A; Kirkner G; Hughes ME; Lin NU; Mittendorf EA; Schnitt SJ; Tolaney SM; Goel S
    Clin Cancer Res; 2024 Oct; 30(20):4768-4779. PubMed ID: 39136550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancer.
    Matsumoto N; Tajima K; Takahashi F; Mitsuishi Y; Wirawan A; Hidayat M; Winardi W; Wibowo A; Hayakawa D; Izumi K; Kanamori K; Miyashita Y; Handa T; Asao T; Ko R; Shukuya T; Shimada N; Takamochi K; Hayashi T; Suzuki K; Takahashi K
    Respir Investig; 2024 Sep; 62(5):901-909. PubMed ID: 39116798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.
    Liu JC; Granieri L; Shrestha M; Wang DY; Vorobieva I; Rubie EA; Jones R; Ju Y; Pellecchia G; Jiang Z; Palmerini CA; Ben-David Y; Egan SE; Woodgett JR; Bader GD; Datti A; Zacksenhaus E
    Cell Rep; 2018 Apr; 23(1):112-126. PubMed ID: 29617654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics.
    Lyu J; Yang EJ; Zhang B; Wu C; Pardeshi L; Shi C; Mou PK; Liu Y; Tan K; Shim JS
    Nat Commun; 2020 Oct; 11(1):5105. PubMed ID: 33037191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
    Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
    Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
    Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide relationships between TAF1 and histone acetyltransferases in Saccharomyces cerevisiae.
    Durant M; Pugh BF
    Mol Cell Biol; 2006 Apr; 26(7):2791-802. PubMed ID: 16537921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletions of Retinoblastoma 1 (Rb1) and Its Repressing Target S Phase Kinase-associated protein 2 (Skp2) Are Synthetic Lethal in Mouse Embryogenesis.
    Zhao H; Wang H; Bauzon F; Lu Z; Fu H; Cui J; Zhu L
    J Biol Chem; 2016 May; 291(19):10201-9. PubMed ID: 26966181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
    Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
    Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.
    Fagan-Solis KD; Pentecost BT; Gozgit JM; Bentley BA; Marconi SM; Otis CN; Anderton DL; Schneider SS; Arcaro KF
    J Cell Physiol; 2014 Sep; 229(9):1160-9. PubMed ID: 24443386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
    Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
    Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
    Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
    Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.